164P TQB2450 plus anlotinib combined with paclitaxel and cisplatin as first-line treatment of advanced esophageal squamous cell carcinoma (ESCC): A single-arm, multicenter phase Ⅱ trial. (December 2022) - Wang, J.; Li, N.; Guo, Y.; Cheng, Y.; Li, B.; Luo, S.